News | August 13, 2024
Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
Morepen Labs successfully raised Rs. 200 Crore through QIP
Morepen Labs successfully raised Rs. 200 Crore through QIP
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Shivani Satish Wagh takes on the role of Joint Managing Director
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Decision on EU marketing authorisation for this population expected by September 2024
Subscribe To Our Newsletter & Stay Updated
